Business Description
Xencor Inc
NAICS : 325412
SIC : 2834
ISIN : US98401F1057
Total Employee Number:
260Description
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.54 | |||||
Equity-to-Asset | 0.7 | |||||
Debt-to-Equity | 0.34 | |||||
Debt-to-EBITDA | -1.33 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 1.4 | |||||
Beneish M-Score | -3.83 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -15 | |||||
3-Year EBITDA Growth Rate | 6 | |||||
3-Year EPS without NRI Growth Rate | -21.5 | |||||
3-Year FCF Growth Rate | -80.4 | |||||
3-Year Book Growth Rate | -10 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -30.2 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.8 | |||||
9-Day RSI | 62.37 | |||||
14-Day RSI | 63.44 | |||||
3-1 Month Momentum % | -4.39 | |||||
6-1 Month Momentum % | -21.27 | |||||
12-1 Month Momentum % | 48.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.57 | |||||
Quick Ratio | 6.57 | |||||
Cash Ratio | 6.06 | |||||
Days Sales Outstanding | 111.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.2 | |||||
Shareholder Yield % | -0.59 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -217.93 | |||||
Net Margin % | -177.1 | |||||
EBITDA Margin % | -135.23 | |||||
FCF Margin % | -193.96 | |||||
OCF Margin % | -191.58 | |||||
ROE % | -28.39 | |||||
ROA % | -20.21 | |||||
ROIC % | -56.86 | |||||
3-Year ROIIC % | -81.74 | |||||
ROC (Joel Greenblatt) % | -152.68 | |||||
ROCE % | -18.57 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 11.97 | |||||
PB Ratio | 2.25 | |||||
Price-to-Tangible-Book | 2.28 | |||||
EV-to-EBIT | -6.28 | |||||
EV-to-EBITDA | -6.78 | |||||
EV-to-Revenue | 9.16 | |||||
EV-to-Forward-Revenue | 8.55 | |||||
EV-to-FCF | -4.72 | |||||
Price-to-GF-Value | 1.65 | |||||
Price-to-Median-PS-Value | 1.06 | |||||
| Price-to-Net-Current-Asset-Value | 4.44 | |||||
| Price-to-Net-Cash | 5.19 | |||||
Earnings Yield (Greenblatt) % | -15.92 | |||||
FCF Yield % | -16.25 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:XNCR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xencor Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 97.36 | ||
| EPS (TTM) ($) | -2.29 | ||
| Beta | 1.1549 | ||
| 3-Year Sharpe Ratio | -0.04 | ||
| 3-Year Sortino Ratio | -0.06 | ||
| Volatility % | 67.36 | ||
| 14-Day RSI | 63.44 | ||
| 14-Day ATR ($) | 0.80125 | ||
| 20-Day SMA ($) | 13.5225 | ||
| 12-1 Month Momentum % | 48.24 | ||
| 52-Week Range ($) | 6.92 - 18.69 | ||
| Shares Outstanding (Mil) | 74.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xencor Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xencor Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 121 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 30 days | ||
| General meeting for 2026 | 2026-06-16 13:00 | 12.21 (-0.81%) | ||
| Guidance call for 2026 | 2026-05-12 15:00 | 12.79 (-1.69%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 12.85 (-4.74%) | ||
| Xencor XmAb942 and XmAb412 | 2026-05-05 08:00 | 13.36 (+4.29%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-11 11:30 | 11.98 (+0.25%) | ||
| Guidance call for 2026 | 2026-03-10 10:00 | 11.87 (+5.51%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 15:50 | 12.77 (-5.34%) | ||
| Annual report for 2025 | 2026-02-25 | 11.81 (-0.25%) |
Show
Entries
Xencor Inc Frequently Asked Questions
What is Xencor Inc(XNCR)'s stock price today?
The current price of XNCR is $15.67. The 52 week high of XNCR is $18.69 and 52 week low is $6.92.
When is next earnings date of Xencor Inc(XNCR)?
The next earnings date of Xencor Inc(XNCR) is 2026-08-06 Est..
Does Xencor Inc(XNCR) pay dividends? If so, how much?
Xencor Inc(XNCR) does not pay dividend.
Guru Commentaries on NAS:XNCR
No articles.
Press Release
Articles on Xencor Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers